PMID- 36926379
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230425
IS  - 1918-1523 (Electronic)
IS  - 1203-6765 (Print)
IS  - 1203-6765 (Linking)
VI  - 2023
DP  - 2023
TI  - Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative 
      Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind 
      Clinical Trial.
PG  - 7768704
LID - 10.1155/2023/7768704 [doi]
LID - 7768704
AB  - OBJECTIVE: To evaluate the analgesic efficacy and safety of different does of 
      intravenous ibuprofen (IVIB) in the treatment of postoperative acute pain. 
      METHODS: Patients with an intravenous (IV) patient-controlled analgesia device 
      after abdominal or orthopedic surgery were randomly divided into placebo, IVIB 
      400 mg, and IVIB 800 mg groups. The first dosage of study medicines was given 
      intravenously 30 minutes (min) before surgery ended, followed by six hours (h) 
      intervals for a total of eight doses following surgery. The demographic 
      characteristics and procedure data, cumulative morphine consumption, the visual 
      analog scale (VAS), the area under the curve (AUC) of VAS, patient satisfaction 
      score (PSS), the rates of treatment failure (RTF), and adverse events (AEs) and 
      serious adverse event (SAEs) were recorded during the period of trial. RESULT: A 
      total of 345 patients were enrolled in the full analysis set (FAS), and of 326 
      participants were valid data set (VDS). Demographic characteristics, disease 
      features, and medical history of patients were not significantly different 
      between groups. Total morphine consumption of the IVIB 400 mg group 
      (11.14 +/- 7.14 mg; P = 0.0011) and the IVIB 800 mg group (11.29 +/- 6.45 mg; 
      P = 0.0014) was significantly reduced compared with the placebo group 
      (14.51 +/- 9.19 mg) for 24 h postoperatively, there was no significant difference 
      between the IVIB 400 mg and IVIB 800 mg groups (P = 0.9997). The placebo group 
      had significantly higher VAS and the AUCs of VAS than those in the IVIB 400 mg 
      and the IVIB 800 mg groups at rest and movement for 24 h postoperatively 
      (P < 0.05), and there was no significant difference between the IVIB 400 mg and 
      IVIB 800 mg groups (P > 0.05). RTF was slightly higher in the placebo group than 
      IVIB 400 mg group and 800 mg group, and no statistical significance (P < 0.690). 
      PSS in the IVIB 400 mg (P = 0.0092) and the IVIB 800 mg groups (P = 0.0011) was 
      higher than the placebo group for pain management, there was also no significant 
      difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.456). The 
      incidence of RTF (P = 0.690) and AEs (P > 0.05) were not different among the 
      three groups. CONCLUSION: Intermittent IV administration of ibuprofen 400 mg or 
      800 mg within 24 h after surgery in patients undergoing abdominal and orthopedic 
      surgery significantly decreased morphine consumption and relieved pain, without 
      increasing the incidence of AEs.
CI  - Copyright (c) 2023 Hong-Su Zhou et al.
FAU - Zhou, Hong-Su
AU  - Zhou HS
AUID- ORCID: 0000-0003-3337-8168
AD  - Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, 
      Zunyi, Guizhou 563000, China.
FAU - Li, Ting-Ting
AU  - Li TT
AUID- ORCID: 0000-0001-6041-6719
AD  - Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 
      610044, China.
FAU - Pi, Yu
AU  - Pi Y
AUID- ORCID: 0000-0002-2499-7605
AD  - Department of Anesthesiology, South West Medical University, Luzhou 646000, 
      China.
FAU - Wang, Ting-Hua
AU  - Wang TH
AUID- ORCID: 0000-0003-2012-8936
AD  - Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, 
      Zunyi, Guizhou 563000, China.
AD  - Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 
      610044, China.
FAU - Liu, Fei
AU  - Liu F
AUID- ORCID: 0000-0002-9970-1338
AD  - Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 
      610044, China.
FAU - Xiong, Liu-Lin
AU  - Xiong LL
AUID- ORCID: 0000-0002-1623-5969
AD  - Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, 
      Zunyi, Guizhou 563000, China.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230307
PL  - United States
TA  - Pain Res Manag
JT  - Pain research & management
JID - 9612504
RN  - WK2XYI10QM (Ibuprofen)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Analgesics)
RN  - 76I7G6D29C (Morphine)
SB  - IM
MH  - Humans
MH  - *Ibuprofen/therapeutic use
MH  - *Acute Pain/drug therapy/etiology
MH  - Analgesics, Opioid/therapeutic use
MH  - Analgesics/therapeutic use
MH  - Pain, Postoperative/drug therapy/etiology
MH  - Morphine/therapeutic use
MH  - Double-Blind Method
PMC - PMC10014159
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2023/03/18 06:00
MHDA- 2023/03/21 06:00
PMCR- 2023/03/07
CRDT- 2023/03/17 02:49
PHST- 2022/09/14 00:00 [received]
PHST- 2023/01/05 00:00 [revised]
PHST- 2023/02/07 00:00 [accepted]
PHST- 2023/03/17 02:49 [entrez]
PHST- 2023/03/18 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2023/03/07 00:00 [pmc-release]
AID - 10.1155/2023/7768704 [doi]
PST - epublish
SO  - Pain Res Manag. 2023 Mar 7;2023:7768704. doi: 10.1155/2023/7768704. eCollection 
      2023.